{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000132","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.390620+00:00","generated_at":"2026-05-30T02:03:28.049689+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone","bullets":["FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.","FDA approval triggers $30M milestone payment from Blackstone to Autolus.","Cash and equivalents totaled $657.1M at Sep 30, 2024, up from $239.6M at Dec 31, 2023.","Net loss of $82.1M for Q3 2024 vs $45.8M in Q3 2023; diluted EPS -$0.31.","Matthias Will M.D. appointed Chief Development Officer effective Sep 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000132","json":"https://secwatch.observer/filing/0001730463-24-000132.json","markdown":"https://secwatch.observer/filing/0001730463-24-000132.md","text":"https://secwatch.observer/filing/0001730463-24-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/0001730463-24-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autl-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:03:28.049689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}